Literature DB >> 19927150

Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27.

Jelena Kamilic1, Inge Hamming, Reinhold Kreutz, Juliane Bolbrinker, Wolf-Eberhard Siems, Ibrahim Nassar, Judith C Sluimer, Thomas Walther, Gerjan J Navis, Harry van Goor.   

Abstract

Differential renal expression of a homolog of the angiotensin-converting enzyme (ACE), that is, ACE2, has been implicated as a genetic basis of polygenetic hypertension in the stroke-prone spontaneously hypertensive rat model. However, data on the role of ACE2 in hypertension are still inconclusive. Therefore, we analyzed kidney ACE2 mRNA, ACE2 protein and ACE2 enzyme activities in the adult polygenetic stroke-prone spontaneously hypertensive rat (SHRSP) and the monogenetic TGR(mREN2)27 rat models, in comparison with their normotensive reference strains, Wistar-Kyoto (WKY) and Spraque-Dawley (SD) rats, respectively. Kidney ACE2 mRNA was studied using quantitative real-time reverse transcriptase-PCR (RT-PCR) in cortex and medulla, whereas protein expression was scored semiquantitatively in detail in different renal structures using immunohistochemistry. Furthermore, total renal tissue ACE2 activity was measured using a fluorimetric assay that was specified by the ACE2 inhibitor DX600. In SHRSP and homozygous TGR(mREN2)27 rats with established hypertension, kidney ACE2 mRNA, protein and tissue ACE2 activities were not different from their respective WKY and SD reference strain, respectively. In addition, when we looked at renal localization, we found ACE2 protein to be predominantly present in glomeruli and endothelium with weak staining in distal and negative staining in proximal tubuli. Thus, our data challenge previous work that implicates ACE2 as a candidate gene for hypertension in SHRSP by reporting a significant reduction of ACE2 in the kidneys of SHRSP. Taken together, renal ACE2 is not altered in the SHRSP and TGR(mREN2)27 genetic rat models with established hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19927150     DOI: 10.1038/hr.2009.191

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  11 in total

Review 1.  Angiotensin peptides and nitric oxide in cardiovascular disease.

Authors:  Kaushik P Patel; Harold D Schultz
Journal:  Antioxid Redox Signal       Date:  2012-05-21       Impact factor: 8.401

Review 2.  New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Peptides       Date:  2011-06-14       Impact factor: 3.750

3.  Does ACE2 contribute to the development of hypertension?

Authors:  Mark C Chappell
Journal:  Hypertens Res       Date:  2009-12-18       Impact factor: 3.872

Review 4.  Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.

Authors:  Carmine Savoia; Massimo Volpe; Reinhold Kreutz
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

Review 5.  Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy.

Authors:  Haru Nomura; Sanjaya Kuruppu; Niwanthi W Rajapakse
Journal:  Front Physiol       Date:  2022-01-11       Impact factor: 4.566

Review 6.  Hypertension and COVID-19: Current Evidence and Perspectives.

Authors:  Giovanna Gallo; Valentin Calvez; Carmine Savoia
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-02-20

Review 7.  From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension.

Authors:  Sheila K Patel; Elena Velkoska; Melanie Freeman; Bryan Wai; Terase F Lancefield; Louise M Burrell
Journal:  Front Physiol       Date:  2014-06-24       Impact factor: 4.566

8.  Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: A case-control study.

Authors:  Qi Zhang; Mingyu Cong; Ningning Wang; Xueyan Li; Hao Zhang; Keyong Zhang; Ming Jin; Nan Wu; Changchun Qiu; Jingping Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

Review 9.  ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives.

Authors:  Federica Saponaro; Grazia Rutigliano; Simona Sestito; Lavinia Bandini; Barbara Storti; Ranieri Bizzarri; Riccardo Zucchi
Journal:  Front Mol Biosci       Date:  2020-09-30

Review 10.  Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions.

Authors:  Yujiro Matsuishi; Bryan J Mathis; Nobutake Shimojo; Jesmin Subrina; Nobuko Okubo; Yoshiaki Inoue
Journal:  Biomedicines       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.